Xencor Inc
$ 15.22
-1.49%
26 Dec - close price
- Market Cap 1,086,867,000 USD
- Current Price $ 15.22
- High / Low $ 15.45 / 15.05
- Stock P/E N/A
- Book Value 8.77
- EPS -1.73
- Next Earning Report 2026-03-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.09 %
- ROE -0.20 %
- 52 Week High 24.66
- 52 Week Low 6.92
About
Xencor, Inc. is an innovative clinical-stage biopharmaceutical company based in Monrovia, California, focused on the creation of advanced cytokine and monoclonal antibody therapies to address significant unmet medical needs in oncology and autoimmune diseases. Utilizing its proprietary XmAb technology platform, the company enhances the therapeutic efficacy and safety of its drug candidates, positioning itself effectively within the competitive biopharmaceutical sector. With a promising and diversified pipeline nearing clinical advancement, Xencor is poised to deliver groundbreaking solutions aimed at improving patient outcomes, presenting compelling opportunities for institutional investors seeking exposure in the biopharmaceutical arena.
Analyst Target Price
$28.25
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-25 | 2024-11-05 | 2024-08-05 | 2024-05-09 | 2024-02-27 | 2023-11-07 | 2023-08-03 | 2023-05-08 | 2023-02-23 |
| Reported EPS | -0.08 | -0.41 | -0.66 | -0.62 | -0.71 | -1.07 | -1.11 | -0.31 | -0.4 | -0.37 | -1.02 | -0.2 |
| Estimated EPS | -0.69 | -0.72 | -0.581 | -0.7862 | -0.98 | -0.88 | -0.79 | -0.09 | -0.73 | -0.8 | -0.66 | -0.79 |
| Surprise | 0.61 | 0.31 | -0.079 | 0.1662 | 0.27 | -0.19 | -0.32 | -0.22 | 0.33 | 0.43 | -0.36 | 0.59 |
| Surprise Percentage | 88.4058% | 43.0556% | -13.5972% | 21.1397% | 27.551% | -21.5909% | -40.5063% | -244.4444% | 45.2055% | 53.75% | -54.5455% | 74.6835% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-04 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.6037 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: XNCR
2025-12-27 15:09:46
Xencor VP John Desjarlais sold 73,367 shares of XNCR stock for over $1.15 million, reducing his stake by 23.67%. The biopharmaceutical company reported beating EPS expectations but missing revenue estimates in its last quarterly earnings. Analysts currently rate Xencor as a "Moderate Buy" with a consensus price target of $24.88.
2025-12-25 07:09:54
Xencor, Inc. (NASDAQ:XNCR) has received a "Moderate Buy" consensus rating from ten brokerages, with an average one-year price target of $24.88. The biopharmaceutical company recently beat EPS estimates but missed revenue expectations and remains unprofitable. Institutional investors have increased their stakes in Xencor, whose stock trades at $15.44 with a market cap of approximately $1.10 billion.
2025-12-24 16:09:54
Xencor Senior Vice President and CSO John R. Desjarlais sold 73,367 shares of common stock, netting $1.15 million, after exercising options on December 19. The company has also extended its royalty term on Ultomiris sales through 2028, potentially adding $100M-$120M in revenue, and has seen positive analyst coverage and promising Phase 1 trial results for its XmAb819 antibody.
2025-12-24 09:09:03
Xencor Inc (NASDAQ:XNCR) Senior Vice President and CSO John R. Desjarlais sold 73,367 shares for $1.15 million after exercising options. This insider activity follows several positive developments for Xencor, including an extended royalty term for Ultomiris, an initiated "Buy" rating from Truist Securities, and upgrades from Barclays and RBC Capital due to pipeline progress and promising Phase 1 data for XmAb819.
2025-12-24 00:52:00
This article details a stock analysis for Xencor Inc. (NASDAQ: XNCR), highlighting a weak sentiment across all time horizons supporting a short bias. It outlines three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis emphasizes an exceptional risk-reward short setup targeting a 32.0% downside.
2025-12-18 17:09:56
Barclays has reiterated its "Overweight" recommendation for Xencor (XNCR). Analyst forecasts suggest an 80.82% upside with an average one-year price target of $28.56/share, significantly higher than its current closing price of $15.80. Institutions show a bullish outlook, with overall shares owned decreasing slightly but the put/call ratio indicating optimism.
